Diabetes Care Devices Market - By Product (Blood Glucose Monitoring Devices, Insulin Delivery Devices ), End-Use (Hospitals, Diagnostic Centers) - Global Forecast, 2024

Description

Diabetes Care Devices Market size is projected to expand at 10% CAGR from 2024 to 2032, led by the rising prevalence of diabetes globally, owing to sedentary lifestyles and unhealthy dietary habits. According to the CDC, total 38.4 million people in the U.S. have diabetes. Rising technological developments are promoting the development of more efficient and user-friendly devices for improving patient compliance and adoption.

The growing awareness about the importance of regular monitoring and management of blood glucose levels among diabetic patients will escalate the demand for the devices. The implementation of favorable reimbursement policies for diabetes care in many regions and the growing geriatric population prone to diabetes-related complications will also complement the industry progression.

The diabetes care devices market is segregated into product, end-use, and region.

In terms of product, the market value from the insulin delivery devices segment will rise at 10.2% growth rate until 2032. Innovations in technology are resulting in the development of more user-friendly and convenient insulin delivery devices. The increasing prevalence of diabetes globally, coupled with the rising adoption of insulin therapy are accelerating the appeal of insulin delivery devices. The jump in initiatives to enhance patient adherence to insulin therapy will also amplify the product adoption.

Diabetes care devices industry share from the homecare end-use segment is estimated to witness 10.4% CAGR between 2024 and 2032. This can be credited to the increasing preference for home-based management of diabetes due to the convenience and comfort provided by these devices to homecare patients. Growing technology improvements are encouraging development of compact and easy-to-use devices suitable for home settings, further boosting the product adoption in homecare settings.

Regionally, the Europe diabetes care devices industry size is anticipated to expand at 9.7% growth rate until 2032, on account of the increasing awareness about diabetes management, rising prevalence of diabetes, and the rollout of supportive government initiatives. The development of innovative glucose monitoring systems and insulin delivery devices are enhancing the effectiveness and convenience of diabetes management solutions for patients across the region.

Product Code: 3250

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast calculations
1.5 Data validation
1.6 Data sources
- 1.6.1 Primary
- 1.6.2 Secondary
  - 1.6.2.1 Paid sources
  - 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

2.1 Industry 360-degree synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Growing prevalence of diabetes across the world
  - 3.2.1.2 Rising technological advancements in diabetes care devices
  - 3.2.1.3 Increasing investments by public and private organizations for diabetes care
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High cost of diabetes care devices
  - 3.2.2.2 Rigorous regulatory framework
3.3 Growth potential analysis
3.4 Technological landscape
3.5 Diabetes prevalence estimates and forecast, by region
3.6 Cost of diabetes management, by region
3.7 Product pipeline analysis
- 3.7.1 Diabetes care products in pipeline, 2023
3.8 Reimbursement scenario
- 3.8.1 Coding and reimbursement
- 3.8.2 Reimbursement policies and public healthcare sector insurance coverage for insulin delivery systems
  - 3.8.2.1 U.S.
  - 3.8.2.2 Europe
3.9 Regulatory landscape
- 3.9.1 U.S.
- 3.9.2 Europe
3.10 Technology landscape
- 3.10.1 Advancements in blood glucose monitoring systems
- 3.10.2 Advancements in insulin delivery devices
3.11 Porter's analysis
- 3.11.1 Supplier power
- 3.11.2 Buyer power
- 3.11.3 Threat of new entrants
- 3.11.4 Threat of substitutes
- 3.11.5 Industry rivalry
3.12 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2018 - 2032 ($ Mn)

5.1 Key trends
5.2 Blood glucose monitoring devices
- 5.2.1 Self-monitoring blood glucose meters
- 5.2.2 Continuous glucose monitors
- 5.2.3 Testing strips
- 5.2.4 Lancets
5.3 Insulin delivery devices
- 5.3.1 Insulin pumps
  - 5.3.1.1 Tubed pumps
  - 5.3.1.2 Tubeless pumps
- 5.3.2 Pens
  - 5.3.2.1 Reusable
  - 5.3.2.2 Disposable
- 5.3.3 Pen needles
  - 5.3.3.1 Standard
  - 5.3.3.2 Safety
- 5.3.4 Syringes
- 5.3.5 Other devices

Chapter 6 Market Estimates and Forecast, By End-Use, 2018 - 2032 ($ Mn)

6.1 Key trends
6.2 Hospital
6.3 Ambulatory surgical centers
6.4 Diagnostic centers
6.5 Homecare
6.6 Other end-users

Chapter 7 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

7.1 Key trends
7.2 North America
- 7.2.1 U.S.
- 7.2.2 Canada
7.3 Europe
- 7.3.1 Germany
- 7.3.2 UK
- 7.3.3 France
- 7.3.4 Netherlands
- 7.3.5 Sweden
- 7.3.6 Belgium
- 7.3.7 Denmark
- 7.3.8 Finland
- 7.3.9 Norway
- 7.3.10 Lithuania
- 7.3.11 Latvia
- 7.3.12 Estonia
- 7.3.13 Rest of Europe
7.4 Asia Pacific
- 7.4.1 Japan
- 7.4.2 China
- 7.4.3 India
- 7.4.4 Australia
- 7.4.5 South Korea
- 7.4.6 Rest of Asia Pacific
7.5 Latin America
- 7.5.1 Brazil
- 7.5.2 Mexico
- 7.5.3 Argentina
- 7.5.4 Colombia
- 7.5.5 Chile
- 7.5.6 Peru
- 7.5.7 Rest of Latin America
7.6 Middle East and Africa
- 7.6.1 South Africa
- 7.6.2 Saudi Arabia
- 7.6.3 UAE
- 7.6.4 Turkey
- 7.6.5 Egypt
- 7.6.6 Israel
- 7.6.7 Kuwait
- 7.6.8 Qatar
- 7.6.9 Rest of Middle East and Africa

Chapter 8 Company Profiles

8.1 Abbott Laboratories
8.2 Arkray, Inc.
8.3 Ascensia Diabetes Care Holding AG
8.4 B. Braun Melsungen AG
8.5 Becton Dickinson and Company
8.6 Bionime Corporation
8.7 DarioHealth Corp.
8.8 Dexcom, Inc.
8.9 Dr. Reddy's Laboratories
8.10 Eli Lilly and Company
8.11 F. Hoffmann-La Roche AG
8.12 Insulet Corporation
8.13 LifeScan, Inc.
8.14 Medtronic Plc
8.15 Nova Biomedical, Inc.
8.16 Novo Nordisk A/S
8.17 Pendiq GmBH
8.18 Sanofi
8.19 Sinocare, Inc.
8.20 Tandem Diabetes Care Inc.
8.21 Ypsomed AG

Diabetes Care Devices Market - By Product (Blood Glucose Monitoring Devices, Insulin Delivery Devices ), End-Use (Hospitals, Diagnostic Centers) - Global Forecast, 2024 - 2032